Merck & Co., Inc. Unrecognized Tax Benefits that Would Impact Effective Tax Rate
Merck & Co., Inc. (MRK) had Unrecognized Tax Benefits that Would Impact Effective Tax Rate of $2.50 billion as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate · last filed 2026-02-24
- 2025-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $2.50B.
- 2024-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $2.20B.
- 2023-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $2.30B.
- 2022-12-31: Unrecognized Tax Benefits that Would Impact Effective Tax Rate $1.80B.
| Period end | Unrecognized Tax Benefits that Would Impact Effective Tax Rate |
|---|---|
| 2025-12-31 | $2.50B 10-K · filed 2026-02-24 |
| 2024-12-31 | $2.20B 10-K · filed 2025-02-25 |
| 2023-12-31 | $2.30B 10-K · filed 2024-02-26 |
| 2022-12-31 | $1.80B 10-K · filed 2023-02-24 |
| 2021-12-31 | $1.50B 10-K · filed 2022-02-25 |
| 2020-12-31 | $1.50B 10-K · filed 2021-02-25 |
| 2019-12-31 | $1.10B 10-K · filed 2020-02-26 |
| 2018-12-31 | $1.80B 10-K · filed 2019-02-27 |
| 2017-12-31 | $1.60B 10-K · filed 2018-02-27 |
| 2016-12-31 | $3.30B 10-K · filed 2017-02-28 |
| 2015-12-31 | $3.20B 10-K · filed 2016-02-26 |
| 2014-12-31 | $3.30B 10-K · filed 2015-02-27 |
| 2013-12-31 | $3.30B 10-K · filed 2014-02-27 |
| 2012-12-31 | $3.80B 10-K · filed 2013-02-28 |
| 2011-12-31 | $3.60B 10-K · filed 2012-02-28 |
| 2010-12-31 | $4.20B 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |